Company: MYGN
Filing Date: 2025-04-09
Form Type: DEF 14A
Source: 0000899923-25-000028
Chunk: 72

Company: MYRIAD GENETICS INC
Filing Date: 2025-04-09
Form: DEF 14A
Chunk 72
---
 Change of Control” later in this proxy statement, provide certain benefits to each NEO, other than Mr. Diaz, upon a change-of-control transaction and/or termination of employment with us. Mr. Diaz's employment agreement, which is discussed below, provides for similar benefits upon a change-of-control transaction and/or termination of employment with us.

Mr. Diaz was appointed to the position of President and Chief Executive Officer on August 13, 2020, and entered into an employment agreement with us at that time. As determined by our CHCC, he received a salary of $1,120,875 for the 2024 fiscal year. His incentive cash bonus for the 2024 fiscal year was $1,356,750. On March 14, 2024, Mr. Diaz was granted 246,247 PSUs, which are subject to the achievement of revenue and adjusted EPS targets based on fiscal year 2026 results and relative total stockholder return targets over a three-year measurement period ending December 31, 2026, and 246,248 RSUs, which are subject to time-based vesting requirements (33.3% vesting each year over a three-year period).

On February 24, 2025, Mr. Diaz notified the Board that he will step down from his position as our President and Chief Executive Officer, and resign from the Board, in each case, effective as of the Transition Effective Date. In connection with Mr. Diaz's resignation, we entered into a consulting agreement with Mr. Diaz under which Mr. Diaz has agreed to serve as an advisor to the Company for one year following the Transition Effective Date to help ensure a smooth transition of his duties. Pursuant to the consulting agreement, (i) we will pay Mr. Diaz his prorated short-term bonus under his current employment agreement at target through the Transition Effective Date of $375,000 (payable in 12 equal monthly installments over the consulting term) and (ii) each of Mr. Diaz’s outstanding equity awards will remain eligible for vesting through the end of the consulting term and remain exercisable in accordance with their respective terms under the Company’s 2017 Employee, Director, and Consultant Equity Incentive Plan.

Mr. Leffler was appointed to the position of Chief Financial Officer on January 29, 2024, and entered into an employment agreement with us in connection therewith. Pursuant to the terms of Mr. Leffler's employment agreement, Mr. Leffler's annual base